Advertisement
Home Tags Sickle-Cell Anemia

Tag: Sickle-Cell Anemia

For African-Americans

Sickle Cell Trait Not Linked to Stroke in African-Americans

Meta-analysis of four cohorts shows sickle cell trait not linked to incidence of ischemic stroke
In patients with sickle cell anemia

Ceruloplasmin ID’d As Marker of Kidney Disease in Sickle Cell

Findings part of proteomic analysis of urine in patients with sickle cell disease
Adherence to antibiotic guidelines for acute chest syndrome in children with sickle cell disease varies widely

Antibiotic Rx Adherence Varies Widely in Sickle Cell Care

Guideline-adherent therapy tied to fewer 30-day readmissions
The U.S. Food and Drug Administration has approved Endari (L-glutamine oral powder) to treat patients with sickle cell disease.

FDA Approves Endari for the Treatment of Sickle Cell Disease

First treatment approved for patients with sickle cell disease in almost 20 years
In a brief report published in the March 2 issue of the New England Journal of Medicine

Gene Therapy Described in a Patient With Sickle Cell Disease

But treatment has only been given to one patient so far
Hemoglobin A1c measurements may be less accurate in black people who have sickle cell trait

Sickle Cell Trait May Affect Reliability of HbA1c Readings

HbA1c levels significantly lower than in people without sickle cell trait
High-dose crizanlizumab treatment is associated with a significantly lower rate of sickle cell-related pain crises than placebo

ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab

Lower rate of crises per year; longer median time to first, second crises with high-dose therapy
Sickle cell trait is not associated with a higher risk of death than absence of the trait

Sickle Cell Trait Doesn’t Up Mortality Risk in U.S. Soldiers

However, SC trait was linked with significantly higher risk of exertional rhabdomyolysis
Hydroxyurea may help preserve lung function in children with sickle cell disease

ATS: Hydroxyurea Can Up Lung Function in Sickle Cell Disease

Drug slowed down the annual decline children had been showing before starting treatment
The rate of vaso-occlusive crisis events is not significantly lower for children and adolescents with sickle-cell anemia receiving prasugrel versus placebo

ASH: Prasugrel Doesn’t Cut Vaso-Occlusive Crisis in Sickle Cell

Rate of vaso-occlusive crisis events is not lower for children receiving prasugrel versus placebo